There is breaking news out of Santa Monica today as MRC member charity, The Prostate Cancer Foundation has helped fund a groundbreaking study that has profound implications.
SANTA MONICA, Calif., July 7, 2016 /PRNewswire-USNewswire/ — One in nine (12%) men with metastatic prostate cancer carry inherited mutations in DNA damage repair (DDR) genes, reports a new study funded in part by the Prostate Cancer Foundation (PCF). These practice-changing findings suggest that all metastatic prostate cancer patients should undergo screening for DDR defects, and that families of men found to have these mutations seek genetic counseling.
These results were published on Wednesday, July 6, 2016 in the New England Journal of Medicine.
“The implications of these groundbreaking findings are profound,” said Jonathan W. Simons, MD, president and CEO, Prostate Cancer Foundation. “Not only will they advance precision medicine for prostate cancer by identifying who may benefit from targeted treatment, but also new recommendations for screening can help determine who is at the greatest risk for this disease so we can intervene. Also, we estimate more than 12,000 U.S. families facing prostate cancer are carrying these genes in their children and grandchildren.”
“I think every man today with metastatic prostate cancer should have genetic testing, regardless of age or family history,” saidPeter Nelson, MD, of Fred Hutchinson Cancer Research Center, and Professor of Medical Oncology at the University ofWashington and the Genitourinary Oncology Clinical Research Director of the Seattle Cancer Care Alliance. Nelson led the study on behalf of the PCF International Prostate Cancer Dream Team.
Click here to read the full press release from the Prostate Cancer Foundation.